These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

171 related items for PubMed ID: 7688829

  • 1. A randomized phase II trial of flutamide vs chlormadinone acetate in previously untreated advanced prostatic cancer. The Japan Flutamide Study Group.
    Akaza H, Usami M, Kotake T, Koiso K, Aso Y.
    Jpn J Clin Oncol; 1993 Jun; 23(3):178-85. PubMed ID: 7688829
    [Abstract] [Full Text] [Related]

  • 2. [Pretreatment with chlormadinone acetate in prostate cancer patients treated with a luteinizing hormone-releasing hormone analogue].
    Yamamoto A, Sumiyoshi Y, Miyake N, Yokozeki H, Kanayama H, Kagawa S.
    Hinyokika Kiyo; 1998 Aug; 44(8):557-63. PubMed ID: 9783191
    [Abstract] [Full Text] [Related]

  • 3. Inhibition of disease flare with diethylstilbestrol diphosphate and chlormadinone acetate administration for two weeks prior to slow-releasing leuprolide acetate in prostatic cancer patients.
    Ohuchi H, Noguchi K, Kinoshita Y, Hosaka M, Kawasaki C, Miura T, Kondo I, Harada M.
    Hinyokika Kiyo; 2000 Aug; 46(8):531-6. PubMed ID: 11019371
    [Abstract] [Full Text] [Related]

  • 4. Flutamide monotherapy as primary treatment in advanced prostatic carcinoma.
    Delaere KP, Van Thillo EL.
    Semin Oncol; 1991 Oct; 18(5 Suppl 6):13-8. PubMed ID: 1948117
    [Abstract] [Full Text] [Related]

  • 5. [Clinical evaluation of flutamide, a pure antiandrogen, in prostatic cancer phase II dose-finding study].
    Aso Y, Akaza H, Koiso K, Kameyama S, Koyanagi T, Kawai T, Kumamoto Y, Tazaki H, Funyu T, Oshima H.
    Hinyokika Kiyo; 1993 Apr; 39(4):391-403. PubMed ID: 8503339
    [Abstract] [Full Text] [Related]

  • 6. Flutamide versus orchidectomy in the treatment of metastatic prostate carcinoma.
    Boccon-Gibod L, Fournier G, Bottet P, Marechal JM, Guiter J, Rischman P, Hubert J, Soret JY, Mangin P, Mallo C, Fraysse CE.
    Eur Urol; 1997 Apr; 32(4):391-5; discussion 395-6. PubMed ID: 9412794
    [Abstract] [Full Text] [Related]

  • 7. [Clinical evaluation of CMA in the treatment of prostatic cancer].
    Fukuoka H, Goto A, Murai T, Satomi Y, Moriyama M, Senga Y, Shirai K, Nakao H.
    Hinyokika Kiyo; 1986 Dec; 32(12):1821-30. PubMed ID: 2435131
    [Abstract] [Full Text] [Related]

  • 8. Phase I-II trial evaluating combined intensity-modulated radiotherapy and in situ gene therapy with or without hormonal therapy in treatment of prostate cancer-interim report on PSA response and biopsy data.
    Teh BS, Ayala G, Aguilar L, Mai WY, Timme TL, Vlachaki MT, Miles B, Kadmon D, Wheeler T, Caillouet J, Davis M, Carpenter LS, Lu HH, Chiu JK, Woo SY, Thompson T, Aguilar-Cordova E, Butler EB.
    Int J Radiat Oncol Biol Phys; 2004 Apr 01; 58(5):1520-9. PubMed ID: 15050332
    [Abstract] [Full Text] [Related]

  • 9. Prostate-specific antigen changes as a result of chlormadinone acetate administration to patients with benign prostatic hyperplasia: a retrospective multi-institutional study.
    Fujimoto K, Hirao Y, Masumori N, Arai Y, Yamanaka H, Kato T, Miyazawa K.
    Int J Urol; 2006 May 01; 13(5):543-9. PubMed ID: 16771723
    [Abstract] [Full Text] [Related]

  • 10. [Clinical phase I and phase II study on a sustained release formulation of leuprorelin acetate (TAP-144-SR), an LH-RH agonist, in patients with prostatic carcinoma. Collaborative++ Studies on Prostatic Carcinoma by the Study Group for TAP-144-SR].
    Niijima T, Aso Y, Akaza H, Fujita K, Fuse H, Hosaka M, Isurugi K, Kamidono S, Katayama T, Kawabe K.
    Hinyokika Kiyo; 1990 Nov 01; 36(11):1343-60. PubMed ID: 2126912
    [Abstract] [Full Text] [Related]

  • 11. [Effects of anti-androgens on sexual function. Double-blind comparative studies on allylestrenol and chlormadinone acetate Part I: Nocturnal penile tumescence monitoring].
    Kumamoto Y, Yamaguchi Y, Sato Y, Suzuki R, Tanda H, Kato S, Mori K, Matsumoto H, Maki A, Kadono M.
    Hinyokika Kiyo; 1990 Feb 01; 36(2):213-26. PubMed ID: 1693037
    [Abstract] [Full Text] [Related]

  • 12. [Clinical usefulness of chlormadinone acetate as an alternative antiandrogen therapy for prostate cancer relapse after combined androgen blockade therapy].
    Ehara H, Katoh S, Nakane K, Katoh T, Takada T, Kojima K, Kamei S, Hagiwara N, Yuhara K, Takahashi Y, Fujimoto Y, Fujihiro S, Kanimoto Y, Deguchi T.
    Hinyokika Kiyo; 2009 Apr 01; 55(4):199-203. PubMed ID: 19462824
    [Abstract] [Full Text] [Related]

  • 13. Prevention of the initial testosterone surge induced by a luteinizing hormone-releasing hormone analogue in prostate cancer patients: the endocrinological effects of pretreatment with chlormadinone acetate.
    Yamamoto A, Sumiyoshi Y, Miyake N, Yokozeki H, Kanayama H, Kagawa S.
    J Med Invest; 1999 Feb 01; 46(1-2):55-8. PubMed ID: 10408158
    [Abstract] [Full Text] [Related]

  • 14. [Clinical study on chlormadinone acetate alone followed by combination with LH-RH analogue for prostatic cancer: effects on lipid metabolism].
    Shimada M, Uchida H, Kasahara T, Fuji K, Ogawa Y, Yoshida H, Hamajima T, Matsuda N, Ikeuchi T, Kai Y, Hiramori M, Hoshino M, Inoue K, Higaki Y.
    Hinyokika Kiyo; 1998 Jul 01; 44(7):525-32. PubMed ID: 9752613
    [Abstract] [Full Text] [Related]

  • 15. Bilateral orchiectomy with or without flutamide for metastatic prostate cancer.
    Eisenberger MA, Blumenstein BA, Crawford ED, Miller G, McLeod DG, Loehrer PJ, Wilding G, Sears K, Culkin DJ, Thompson IM, Bueschen AJ, Lowe BA.
    N Engl J Med; 1998 Oct 08; 339(15):1036-42. PubMed ID: 9761805
    [Abstract] [Full Text] [Related]

  • 16. [Hormonal environment following treatment with a small dose of estrogen--small dose of estrogen alone and in combination with an anti-androgen].
    Hayashi T, Taki Y, Ikai K, Hiura M, Kiriyama T.
    Hinyokika Kiyo; 1987 Jul 08; 33(7):1035-42. PubMed ID: 2446483
    [Abstract] [Full Text] [Related]

  • 17. Combined androgen blockade in the management of advanced prostate cancer: a sensible or ostensible approach.
    Ansari MS, Gupta NP, Hemal AK, Dogra PN, Seth A.
    Int J Urol; 2004 Dec 08; 11(12):1092-6. PubMed ID: 15663681
    [Abstract] [Full Text] [Related]

  • 18. Combined low-dose flutamide plus finasteride vs low-dose flutamide monotherapy for recurrent prostate cancer: a comparative analysis of two phase II trials with a long-term follow-up.
    Bañez LL, Blake GW, McLeod DG, Crawford ED, Moul JW.
    BJU Int; 2009 Aug 08; 104(3):310-4. PubMed ID: 19239458
    [Abstract] [Full Text] [Related]

  • 19. Characterization of patients with androgen-independent prostatic carcinoma whose serum prostate specific antigen decreased following flutamide withdrawal.
    Herrada J, Dieringer P, Logothetis CJ.
    J Urol; 1996 Feb 08; 155(2):620-3. PubMed ID: 8558675
    [Abstract] [Full Text] [Related]

  • 20. Safety and efficacy of the specific endothelin-A receptor antagonist ZD4054 in patients with hormone-resistant prostate cancer and bone metastases who were pain free or mildly symptomatic: a double-blind, placebo-controlled, randomised, phase 2 trial.
    James ND, Caty A, Borre M, Zonnenberg BA, Beuzeboc P, Morris T, Phung D, Dawson NA.
    Eur Urol; 2009 May 08; 55(5):1112-23. PubMed ID: 19042080
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.